JNJ — Johnson & Johnson Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeLarge CapNeutral

Annual income statement for Johnson & Johnson, fiscal year end - December 28th, USD millions except per share, conversion factor applied.

	R2022 January 2nd	2023 December 31st	R2023 January 1st	2024 December 29th	2025 December 28th
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	PRESS
Standards:	USG	USG	USG	USG	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	78,740	85,159	79,990	88,821	94,193
Cost of Revenue
Gross Profit	55,338	58,915	55,394	61,385	63,937
Selling / General / Administrative Expenses
Research And Development
Operating Interest Expense / Income
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	59,562	70,097	60,631	72,134	61,612
Operating Profit	19,178	15,062	19,359	16,687	32,581
Net Income Before Taxes	19,178	15,062	19,359	16,687	32,581
Provision for Income Taxes
Net Income After Taxes	17,801	13,326	16,370	14,066	26,804
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	20,878	35,153	17,941	14,066	26,804
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	20,878	35,153	17,941	14,066	26,804
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	7.14	8.33	7.29	8.33	8.83
Dividends per Share